Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIS370
- Development stage
- Unknown
- Lead developer
- Visterra
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VIS370 is a monoclonal antibody currently in Phase 1 clinical development by Visterra, a subsidiary of Otsuka Pharmaceutical. It is being investigated for the treatment of various immune-mediated diseases. The specific molecular target and mechanism of action for VIS370 have not been publicly disclosed by the developer. The drug was engineered using Visterra's proprietary Hierotope platform, which utilizes computational and experimental tools to identify and target unique, conserved epitopes on complex proteins that are traditionally difficult to drug, aiming to create highly specific and potent therapeutic candidates.
Beyond the preview
Go deeper on VIS370.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIS370.